Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
Authors:
Top Cited Papers
- 23 August 2024
- journal article
- review article
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 21 (10) , 743-761
Abstract
Anti-oestrogen-based therapies, often combined with a CDK4/6 inhibitor, are the current standard-of-care first-line therapy for patients with advanced-stage hormone receptor-positive (HR+) breast cancer. Resistance to anti-oestrogen agents inevitably occurs, mediated by oestrogen receptor (ER)-dependent or ER-independent mechanisms that drive tumour progression. Emerging endocrine therapies include, but are not limited to, next-generation oral ER degraders and proteolysis targeting chimeras, which might be particularly effective in patients with ESR1-mutant breast cancer. Furthermore, cancers harbouring driver alterations in oncogenic signalling pathways, including AKT and PI3K, might be susceptible to novel combination strategies involving targeted inhibitors. Next-generation CDK2/4 inhibitors are an area of active clinical investigation, and efforts are ongoing to evaluate the role of sequential CDK inhibition. Approved and emerging antibody–drug conjugates exploiting novel target antigens have also demonstrated promising clinical activity. These novel agents, as well as further identification and characterization of predictive biomarkers, will hopefully continue to improve clinical outcomes, reduce the incidence of toxicities, and limit the extent of overtreatment in this population. In this Review, we describe the evolving treatment paradigm for patients with metastatic HR+ breast cancer in light of the growing armamentarium of drugs and biomarkers that will help to shape the future therapeutic landscape. These strategies are expected to involve tumour molecular profiling to enable the delivery of precision medicine.Keywords
This publication has 174 references indexed in Scilit:
- Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2Annals of Oncology, 2023
- Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trialAnnals of Oncology, 2023
- 273P A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2- early breast cancer (EBC): Final analysis from EMBER-2Annals of Oncology, 2023
- Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancerBreast Cancer Research and Treatment, 2022
- Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1Annals of Oncology, 2021
- Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trialAnnals of Oncology, 2020
- The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs)ChemMedChem, 2020
- Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-upBreast Cancer Research and Treatment, 2019
- Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid TumorsJAMA Oncology, 2016
- Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolismCancer, 2009